About us

Who we are

Huayi was formed in 2006 as a joint venture between a UK-based generic pharmaceutical company and a Chinese fine chemical supplier with a view to creating an independent export-oriented Chinese manufacturer. We were granted our EU Good Manufacturing Practice (GMP) Certificate in 2010 following inspection by the UK Medicines and Healthcare Products Regulatory Agency (MHRA).

We have been able to ensure continued adherence to these high standards and passed two further re-inspections by the MHRA. Our dedication to manufacturing products of the highest quality can also be demonstrated by our facilities passing quality inspections by many customers including Novartis, Teva, Wockhardt, Genesis and Krka.

What is our mission?

Huayi’s mission is to manufacture to the highest quality standards, delivering affordable medicines to healthcare systems and health benefits to patients. We act with responsibility and integrity while providing excellent service to our customers and business partners. We provide security and fulfillment to our employees and strive for excellence in all that we do. We are accountable to our shareholders and make a profit for them over the long term by innovating and investing.

Why become our partner?

Since our establishment, we have completed site transfers of over 50 products and supply a billion doses a year to European customers. We have successfully developed dossiers for Europe resulting in granted marketing authorisations.

We have recently expanded our capability to develop products to Chinese standards also and can produce dossiers that meet both European and Chinese requirements. Together with our associated company Velocyte, we can also offer bio-equivalence studies in China to seamlessly complete the clinical part of the development.

Huayi is committed to upgrading and developing our services. We aim to increase our current manufacturing capacity from 3 billion units to 5 billion units to satisfy demand. We are building new facilities for high-potency and oral liquid manufacturing scheduled for production in 2020.

Partner with us
common 02 Created with Sketch.

API characterisation

common 02 Created with Sketch.

Analytical method development

common 02 Created with Sketch.

Formulation development

common 02 Created with Sketch.

Scale up

common 02 Created with Sketch.

Validation

common 02 Created with Sketch.

Bio-equivalence studies in China through our partner company

common 02 Created with Sketch.

Contract manufacturing and commercial supply

common 02 Created with Sketch.

Full regulatory compliance (toxicological assessment, serialisation etc.)

Research & Development

We are experienced in technology transfers and scale-up process for commercial production. Having transferred over 50 products for our customers and registering almost 100 strengths to date, we are prepared to take on new challenges in pharmaceutical development with our experienced team from Huayi China-Europe Pharmaceutical Research Institute.

Read More

01 / 04

Quality Management

Huayi’s QA team is committed to ensuring your project adheres to EU cGMP standards at every step of production from development to commercial manufacture. We will work hard to ensure that your project will be completed on time to the highest quality and stay focused and communicative throughout the process.

Read More

02 / 04

Contract Manufacturing

In 2018, our contract manufacturing output reached 1.6 billion units. Huayi manufactures solid oral dosage forms including film-coated, sugar-coated, enteric-coated, effervescent, soluble, chewable and buccal tablets as well as capsules. Our high-potency and liquid preparation facilities will be ready in 2020.

Read More

03 / 04

Integrated Services

We offer bioequivalence studies for your next project in China. Through our partners Weida Clinical Research and Velocyte Analytical Technology, we can conduct clinical trials, biological sample testing, dissolution profiling and stability studies. We can then scale-up from the test batch to commercial production.

Read More

04 / 04